オプションチェーンは、Easterly Government Propsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Easterly Government Propsの市場センチメントを評価します。.

Easterly Government Props (NYSE:DEA) 株価情報, オプションチェーン

Easterly Government Props

Easterly Government Properties Inc is a real estate investment trust. It is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. The company generates all its revenue by leasing its properties to such agencies.

Easterly Government Properties, Inc. Common Stock

Easterly Government Properties Inc

DEAPcoin

DEALERADVANCE INC NEW by DealerAdvance, Inc.

DealerAdvance Inc

DEAR CASHMERE HOLDING CO by Dear Cashmere Holding Co.

Dear Cashmere Holding Co

The Trump administration launched an immigration enforcement blitz in Chicago on Sunday, Immigration and Customs Enforcement (ICE) confirmed in a statement.
ICE agents are expected to be joined by officials from several more agencies in the multi-day operation that will soon spread across the country, seemingly beginning with Democratic-run states and cities.
The Chicago operation is part of a broader effort to beef up ICE in terms of resources and agents, as the Trump administration launches its nationwide crackdown toward fulfilling <a href="https://www.benzinga.com/news/25/01/43216758/well-go-as-far-as-im-allowed-trumps-plan-with-immigrants-starts-with-1-million-deportations">President Donald Trump&#8216;s vow</a> to deport one million people.  
"U.S. Immigration and Customs Enforcement, along with federal partners, including the FBI, ATF, DEA, CBP and the U.S. Marshals Service, began conducting enhanced targeted operations today in Chicago to enforce U.S. immigration law and preserve public safety and national security by keeping potentially dangerous criminal aliens out of our communities," the ICE <a href="https://www.ice.gov/news/releases/statement-us-immigration-and-customs-enforcement">statement</a> reads.
<h2 class="wp-block-heading">Dangerous Criminal Aliens? The Governor Begs To Differ</h2>
Illinois Gov. JB Pritzker (D) <a href="https://www.cnn.com/2025/01/26/politics/video/sotu-pritzker-on-planned-chicago-immigration-raids">told CNN's Dana Bash on Sunday</a> that he too wants violent criminals out of the country, but he expressed concern about how the Trump administration is carrying out operations.
"If that's who they're picking up, we're all for it." But, Prizker said, &#8220;they're going after people who are law-abiding, who are holding down jobs, who have families here, who may have been here for a decade or two decades. Why are we going after them? These are not people who are causing problems in our country.&#8221;
Read Also: <a href="https://www.benzinga.com/news/25/01/43216758/well-go-as-far-as-im-allowed-trumps-plan-with-immigrants-starts-with-1-million-deportations">&#8216;We&#8217;ll Go As Far As I&#8217;m Allowed&#8217;: Trump&#8217;s Plan With Immigrants Starts With 1 Million Deportations</a>
The Chicago Police Department said in a statement to <a href="https://www.cnn.com/2025/01/26/politics/chicago-immigration-trump-ice/index.html">CNN</a> it does not document immigration status, and in accordance with its "Welcoming City Ordinance," and that it "does not share information with federal immigration authorities." 
"We will not intervene or interfere with any other government agencies performing their duties," the Chicago PD statement reads.
Meanwhile, on Saturday U.S. Army troops patrolled Eagle Pass, Texas, reported CNN. following Trump's order to <a href="https://www.benzinga.com/markets/cannabis/25/01/43219037/texas-gov-abbott-wants-11-billion-border-security-reimbursement-protecting-the-rest-of-america-was-expensive">deploy 1,500 additional soldiers</a> to the U.S.-Mexico border, raising the total to 4,000. 
Now Read:
<ul>
<li><a href="https://www.benzinga.com/news/25/01/43137164/trumps-immigration-raids-will-disrupt-chicagos-economy-pritzker-says">Trump&#8217;s Immigration Raids Could Disrupt Key Sectors Of Chicago&#8217;s Economy: Pritzker Says To Focus On Criminals, Not Law-Abiding Workers</a></li>
</ul>
Photo courtesy of Chicago DEA

Government

News

Politics

Trump's Immigration Enforcement Raids Begin In Chicago: Gov. Pritzker Concerned Innocents Could Be Targeted

Sen. <a href="https://www.benzinga.com/topic/elizabeth-warren">Elizabeth Warren</a> (D-Mass.) sent a detailed letter to <a href="https://www.benzinga.com/topic/elon-musk">Elon Musk</a>, chair of the newly established Department of Government Efficiency (DOGE) with <a href="https://www.benzinga.com/government/regulations/25/01/43182640/elizabeth-warren-lists-changes-for-elon-musks-doge-department-urges-guantanamo-closure-due-to-hundreds-of-millions-in-annual-costs">numerous suggestions</a> for slashing federal spending.
Warren outlined proposals she said could save the federal government upwards of $2 trillion over the next decade. Among her recommendations was scaling back federal enforcement against marijuana users and businesses, which she called an example of "wasteful spending."
"The United States could save hundreds of millions of dollars annually by cutting unnecessary federal enforcement actions and detention," Warren wrote in the <a href="https://www.warren.senate.gov/imo/media/doc/letter_to_doge_rerecommendationstosave2trillionoverthenext10years.pdf">Thursday letter</a> to the billionaire Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO. 
Warren criticized federal agencies like the <a href="https://www.benzinga.com/topic/drug-enforcement-administration">Drug Enforcement Administration</a> (DEA) and Customs and Border Protection (CBP) for continuing to target legal marijuana businesses and seize cannabis plants. "These arrests and seizures unnecessarily drain federal resources," Warren said. 
When the DEA <a href="https://www.benzinga.com/markets/cannabis/23/07/33156524/dea-turns-50-unveiling-the-ineffectiveness-of-the-ongoing-war-on-drugs-now-what" target="_blank" rel="noreferrer noopener">celebrated its 50th anniversary&nbsp;</a>in 2023, it had spent over $1 trillion partly to enforce&nbsp;Richard Nixon&#8217;s&nbsp;1970 Controlled Substances Act, the cornerstone of his&nbsp;<a href="https://www.benzinga.com/topic/war-on-drugs" target="_blank" rel="noreferrer noopener">War on Drugs</a>.
Warren recommended to Musk that both the Departments of Justice and Homeland Security could also conserve resources by deprioritizing arrests and other actions targeting marijuana possession in jurisdictions where it's legal under state law. 
"For example, almost half of states have legalized recreational marijuana, yet federal arrests for marijuana possession account for roughly a quarter of all drug possession arrests, even though federal sentences for marijuana possession are rare," Warren wrote, referring to FBI data <a href="https://norml.org/blog/2024/09/25/fbi-nearly-one-quarter-of-all-drug-related-arrests-are-for-marijuana-possession/">made public</a> in September 2024.
The senator pointed to reports showing the DEA eradicated over 5.7 million marijuana plants in 2022 and criticized the agency for failing to release updated data on marijuana-related arrests and seizures in 2024. She also highlighted a lawsuit by licensed <a href="https://www.benzinga.com/markets/cannabis/24/10/41561733/lawsuit-against-the-feds-could-set-precedent-on-state-rights-new-mexico-marijuana-firms-move-to-">New Mexico cannabis businesses</a> accusing CBP agents of unconstitutional seizures and detentions.
Last week, <a href="https://www.benzinga.com/general/health-care/25/01/43107039/elizabeth-warren-questions-robert-f-kennedy-jr-on-dangerous-views-pot-legalization-timeline-as-his-senate-hearing-stalls">Warren expressed</a> "serious concerns" about Robert F. Kennedy Jr.'s ability to lead the Department of Health and Human Services. She asked for more information on Kennedy's &nbsp;stance regarding marijuana legalization and other issues including what she called his "dangerous views on vaccine safety and public health, including your baseless opposition to vaccines." 
On Wednesday, Kennedy will appear before the Senate Finance Committee for the first of two confirmation hearings
Meanwhile, the DEA's leadership has drawn scrutiny, with acting administrator Derek Maltz <a href="https://www.benzinga.com/news/global/25/01/43169554/trump-appoints-dea-chief-who-will-bring-ruthless-narco-terrorists-to-justice-not-keen-on-legalizing-cannabis">linking cannabis to issues like school shootings</a>, an unfounded and most agree ludicrous stance. 
In related news, on Saturday the Senate confirmed the nomination of former South Dakota governor&nbsp;<a href="https://www.benzinga.com/topic/kristi-noem">Kristi Noem&nbsp;</a>to lead the Dept. of Homeland Security. 
Now More:
<ul>
<li><a href="https://www.benzinga.com/news/global/25/01/43169554/trump-appoints-dea-chief-who-will-bring-ruthless-narco-terrorists-to-justice-not-keen-on-legalizing-cannabis">Trump Appoints DEA Chief Who Will Bring &#8216;Ruthless Narco-Terrorists To Justice,&#8217; Not Keen On Legalizing Cannabis</a></li>
</ul>
Photo: Shutterstock

Cannabis

Legal

TSLA

Elizabeth Warren To Elon Musk: Cut Unnecessary Federal Cannabis Enforcement And Save Billions

A new poll by NuggMD reveals a stark divide between frequent cannabis consumers and the Drug Enforcement Administration (DEA). According to the survey, conducted between January 16 and January 19, 2025, only 4% of respondents trust the DEA to be an &#8220;unbiased proponent&#8221; for cannabis rescheduling efforts. An overwhelming 96% said they do not.
The survey sampled 677 frequent cannabis users from a list of respondents who opted into NuggMD&#8217;s polls. With a margin of error of ±3.77%, the poll reflects widespread skepticism among a demographic directly affected by cannabis policy. The results came shortly after a federal hearing on cannabis rescheduling <a href="https://www.benzinga.com/25/01/42972524/dea-judge-cancels-marijuana-rescheduling-hearing-amid-disturbing-allegations-of-improper-conduct">was delayed for several months</a>, adding to the uncertainty surrounding the issue.
<h3 class="wp-block-heading">Consumer Trust In The DEA At Historic Lows</h3>
NuggMD, a company focused on medical cannabis evaluations and education, conducted the survey using first-party data from its consumer base. A spokesperson for the company emphasized the importance of this data in understanding public sentiment. &#8220;Cannabis consumers are the people most directly affected by federal cannabis prohibition, and the DEA has the power to enforce those laws,&#8221; said the company's head of communications.
"When an agency you oversee polls at 4% with one of your stakeholder groups, you either have a policy problem, a personnel problem, or both. The current administration needs to choose which problem it has before it can solve it," the statement continued.
This level of distrust highlights a significant challenge for policymakers attempting to navigate cannabis reform. The DEA's reputation as a prohibitionist agency has long been a sticking point for advocates and these survey results suggest the agency may face an uphill battle in regaining credibility with key stakeholders.
<h3 class="wp-block-heading">The Context: Delayed Rescheduling Hearing</h3>
The poll's timing is notable. It was conducted immediately after a federal hearing on rescheduling cannabis—a proposal that would shift the substance from Schedule I to Schedule III under the Controlled Substances Act—was put on hold. This delay has fueled frustrations within the cannabis community, where many see the DEA as a roadblock to meaningful reform.
Cannabis remains classified as a Schedule I substance, alongside drugs like heroin, under federal law. This classification indicates a high potential for abuse and no accepted medical use, despite growing evidence and state-level legalization efforts. Rescheduling cannabis to Schedule III would significantly ease restrictions, potentially allowing for greater research, federal tax deductions and other benefits.
<h3 class="wp-block-heading">Broader Implications</h3>
The findings of the NuggMD poll reveal deeper tensions in the cannabis debate. For decades, the DEA has been viewed as resistant to reform, a perception that persists even as public opinion has shifted dramatically in favor of legalization.
These results also present an opportunity for the Biden administration, which has shown openness to reform. Addressing the mistrust highlighted by this poll could help the administration make meaningful strides in cannabis policy while rebuilding trust with stakeholders.
For now, the message from cannabis consumers is clear: the DEA has significant work to do in proving it can act as a neutral party in rescheduling discussions. Whether through policy changes, personnel shifts, or increased transparency, any attempt to rebuild trust will require swift and decisive action.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/news/global/25/01/43169554/trump-appoints-dea-chief-who-will-bring-ruthless-narco-terrorists-to-justice-not-keen-on-legalizing-cannabis">Trump Appoints DEA Chief Who Will Bring &#8216;Ruthless Narco-Terrorists To Justice,&#8217; Not Keen On Legalizing Cannabis</a></li>
</ul>
Cover image made with AI

96% Of Cannabis Consumers Don't Trust DEA On Rescheduling Efforts: Poll

This week in cannabis was relatively subdued, with the most significant news stemming from Washington, D.C. The Trump administration appointed a controversial new acting DEA administrator, Derek S. Maltz, raising concerns over the future of cannabis rescheduling efforts. Meanwhile, updates from global markets in Germany, Uruguay and the Netherlands highlighted ongoing industry challenges and progress.
Here's a recap of this week's notable developments.
<h3 class="wp-block-heading">Politics</h3>
<h4 class="wp-block-heading">New DEA Leadership Sparks Cannabis Industry Concerns</h4>
The Trump administration <a href="https://www.benzinga.com/news/global/25/01/43169554/trump-appoints-dea-chief-who-will-bring-ruthless-narco-terrorists-to-justice-not-keen-on-legalizing-cannabis">appointed</a> Derek S. Maltz as the acting administrator of the U.S. Drug Enforcement Administration (DEA). A 28-year veteran of the agency, Maltz is known for his hardline stance on cannabis and drug policy. Maltz has criticized cannabis legalization, citing its alleged links to public safety concerns, and accused the Department of Justice of politicizing the cannabis rescheduling process.
"President Trump is off to a fast start as the 47th POTUS with border security and the horrible implications of cartels and drug trafficking in America as an area of major importance, so we are not surprised by the recent appointment of Derek Maltz as the Acting Administrator of the US DEA,&#8221; said Morgan Paxhia, co-founder and Managing Partner of <a href="https://mattio-dot-yamm-track.appspot.com/2pFzd1Qgmrif5VxFI2L_TFQmXMMHIhfA-E3vgz1Zem7pnchqPlAFxJWLFa7a_EcC7Kgp3W3RkyDRkUal94Mbleln_0lctmQ4C_TyNorrTe8gVXAycGFqk6OoFkP3yPy0_lG3I18yoHMnpIsHOSNSKxh8Vm_Nxe6qe0qi3fXcOUXZNoPVfc1jR" target="_blank" rel="noreferrer noopener">Poseidon</a>, a burgeoning cannabis investment fund. &#8220;President Trump has been getting smart on legal cannabis, sees the economic benefits and is pro MAGA and DOGE. We think it is better to focus less on any appointee's dated/biased views on cannabis and more so on POTUS as the primary input for potential legislative reform and as it pertains to the scheduling of cannabis."
This leadership change occurs amid significant delays in the DEA&#8217;s hearings on rescheduling cannabis from a Schedule I to a Schedule III substance under the Controlled Substances Act. Critics fear the Trump administration may abandon the process entirely, which could set back cannabis reform efforts.
Read more <a href="https://www.benzinga.com/news/global/25/01/43169554/trump-appoints-dea-chief-who-will-bring-ruthless-narco-terrorists-to-justice-not-keen-on-legalizing-cannabis">here</a>.
<h3 class="wp-block-heading">Markets</h3>
<h4 class="wp-block-heading">Ispire Technology Announces $10 Million Stock Buyback</h4>
In response to market volatility, Ispire Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPR#NASDAQ">ISPR</a>) unveiled a $10 million stock buyback program to boost shareholder confidence. The company reaffirmed its commitment to long-term growth despite challenges in the broader cannabis market.
<h4 class="wp-block-heading">Earnings Reports On The Horizon</h4>
Cannabis giants are gearing up to report financial results, offering insights into the industry's trajectory:
<ul>
<li>Aurora Cannabis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) will release Q3 2025 earnings on February 5, followed by a call at 8:00 a.m. ET.</li>
<li>Canopy Growth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) will publish its Q3 2025 results on February 7, with a webcast at 10:00 a.m. ET.</li>
<li>Green Thumb Industries (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTCQX">GTBIF</a>) will report Q4 and FY2024 results on February 26, accompanied by a call at 5:00 p.m. ET.</li>
</ul>
<h3 class="wp-block-heading">Global Updates</h3>
<h4 class="wp-block-heading">Uruguay's Cannabis Market Sees Record Sales</h4>
<a href="https://elplanteo.com/uruguay-2024-compradores-cannabis-legal/">Uruguay</a>'s regulated cannabis market hit new highs in 2024, with over 102,000 registered buyers and annual revenues of $30 million. The introduction of high-THC variants like <a href="https://elplanteo.com/uruguay-cannabis-thc-epsilon/">Épsilon</a> (20% THC) drove demand, with pharmacies selling 359 kilograms in just two months after its launch. The country continues to reduce illegal market activity, now capturing 50% of what was once unregulated sales.
<h4 class="wp-block-heading">Aurora Cannabis Launches First German-Cultivated Product</h4>
Aurora debuted its first German-cultivated medical cannabis product, IndiMed, marking a milestone for Europe's largest medical cannabis market. The launch highlights Aurora's commitment to premium, pharmaceutical-grade products, positioning the company as a leader in navigating complex European regulations.
<h4 class="wp-block-heading">Contaminated Cannabis Found In Dutch Coffee Shops</h4>
A study by the Trimbos Institute revealed alarming levels of contaminants in cannabis sold in Dutch coffee shops. Out of 50 samples tested, one-fifth showed microbiological contamination, and one-third contained pesticide residues. Notably, some samples had lead levels nearly six times the permissible limit under forthcoming regulations for a government-licensed trial.
The trial, set to launch in April, aims to improve quality control and curb illegal activity by introducing state-regulated cannabis supply chains. These findings underscore the urgent need for tighter oversight and regulations to ensure consumer safety in one of the world's oldest legal cannabis markets.
<h3 class="wp-block-heading">Celebrity Advocacy: Tyson and Angelos Applaud Trump's Reforms</h3>
Mike Tyson and Weldon Angelos <a href="https://www.benzinga.com/news/legal/25/01/43149460/trumps-cannabis-reform-mike-tyson-weldon-angelos-say-president-can-get-it-done">commended</a> President Trump for his commitment to cannabis reforms, including rescheduling efforts, banking access and clemency for non-violent cannabis offenders. Tyson called the cannabis industry a "multi-billion-dollar market" that fosters economic growth, while Angelos criticized the Biden administration's lackluster efforts on clemency for marijuana-related convictions.
<h3 class="wp-block-heading">Interesting Reads</h3>
To close up the week, below are some other interesting stories to check out:
<ul>
<li><a href="https://www.forbes.com/sites/javierhasse/2025/01/20/how-european-cannabis-seed-companies-are-quietly-taking-over-the-us-market/">How European Cannabis Seed Companies Are Quietly Taking Over The U.S. Market</a></li>
<li><a href="https://www.forbes.com/sites/javierhasse/2025/01/19/worlds-largest-tobacco-company-continues-silent-entry-into-cannabis-is-philip-morris-a-medical-marijuana-supporter/">World's Largest Tobacco Company Continues Silent Entry Into Cannabis: Is Philip Morris A Medical Marijuana Supporter?</a></li>
<li><a href="https://www.benzinga.com/news/global/25/01/43181165/raw-founder-celebrates-87m-legal-victory-in-a-very-peculiar-way-we-rolled-it-up-and-smoked-the-lawsuit-literally">RAW Founder Celebrates $8.7M Legal Victory In A Very Peculiar Way: &#8216;We Rolled It Up And Smoked The Lawsuit, Literally&#8217;</a></li>
<li><a href="https://www.benzinga.com/markets/cannabis/25/01/43165973/the-dea-ruling-was-a-game-changer-why-this-european-cannabis-giant-is-betting-on-the-american-seeds-market">&#8216;The DEA Ruling Was A Game-Changer&#8217;: Why This European Cannabis Giant Is Betting On The American Seeds Market</a></li>
<li><a href="https://www.benzinga.com/markets/cannabis/25/01/42033610/whoopi-goldberg-talks-cannabis-the-planets-greatest-medicine-pain-reliever-and-source-of-joy">Whoopi Goldberg Talks Cannabis: The Planet&#8217;s &#8216;Greatest Medicine&#8230; Pain Reliever And Source Of Joy&#8217;</a></li>
<li><a href="https://www.benzinga.com/general/health-care/25/01/43111246/legal-marijuana-linked-to-drop-in-anxiety-medications-what-it-means-for-pharma-giants">Legal Marijuana Linked To Drop In Anxiety Medications: What It Means For Pharma Giants</a></li>
<li><a href="https://www.benzinga.com/general/health-care/25/01/43107039/elizabeth-warren-questions-robert-f-kennedy-jr-on-dangerous-views-pot-legalization-timeline-as-his-senate-hearing-stalls">Elizabeth Warren Questions Robert F. Kennedy Jr. On &#8216;Dangerous Views,&#8217; Pot Legalization Timeline As His Senate Hearing Stalls</a></li>
</ul>

Earnings

Markets

GTBIF

ISPR

The Week In Cannabis: Trump's DEA Pick, Tyson's Reform Push, Dutch Coffee Shop Crisis And More

Derek Maltz has been appointed acting administrator of the U.S. Drug Enforcement Administration, which places him at the helm of the agency amid <a href="https://www.benzinga.com/government/regulations/25/01/42882766/dea-accused-of-bias-in-cannabis-rescheduling-hearings-weed-stocks-plummeted-in-2024-as-process-drags-on?adt_ei={{email}}&amp;he={{email}}&amp;el=CannabisDaily">contentious debates</a> over cannabis rescheduling and President Donald Trump&#8217;s executive order designating drug cartels as foreign terrorists.
A 28-year DEA veteran, Maltz formerly led the New York Drug Enforcement Task Force, the nation's largest and oldest drug task force. The DEA <a href="https://www.dea.gov/press-releases/2025/01/21/career-special-agent-derek-s-maltz-appointed-lead-us-drug-enforcement">praised Maltz</a> as a staunch advocate in the fight against global drug trafficking and terrorism.
Maltz responded. "DEA is positioned to lead the nation's drug enforcement and intelligence efforts, working closely within the federal, state and local partners, to seize record amounts of illicit drugs; bring the world's most ruthless narco-terrorists to justice; and save American lives by creating a vast network of community partners to help spread critical awareness," Maltz <a href="https://www.dea.gov/press-releases/2025/01/21/career-special-agent-derek-s-maltz-appointed-lead-us-drug-enforcement">said</a> in a DEA press release.&nbsp;
<h1 class="wp-block-heading">Cannabis Rescheduling Process Is A Hot Mess</h1>
Maltz&#8217;s appointment comes as the agency faces scrutiny over its role in a Department of Justice <a href="https://www.benzinga.com/markets/cannabis/24/04/38530190/breaking-dea-reportedly-moves-to-reschedule-cannabis-stocks-rise-sharply-on-the-news">proposal to reschedule cannabis</a> from a Schedule I to a Schedule III drug under the Controlled Substances Act. The process came to a screeching halt in mid-January 2025 when a DEA judge <a href="https://www.benzinga.com/25/01/42972524/dea-judge-cancels-marijuana-rescheduling-hearing-amid-disturbing-allegations-of-improper-conduct">put the process on hold</a> for at least citing serious allegations of misconduct within the DEA.
The new DEA chief has been outspoken in his opposition to cannabis legalization, once tweeting that &#8220;all irresponsible politicians trying to get votes by legalizing marijuana&#8221; should understand the &#8220;negative impacts of smoking this crap.&#8221; Though the Associated Press <a href="https://apnews.com/article/marijuana-pot-dea-legalization-biden-cb7869d3286094f0124de728320d89c1">quoted him in 2024</a> saying, &#8220;If there&#8217;s scientific evidence to support cannabis rescheduling, then so be it. But you&#8217;ve got to let the scientists evaluate it.&#8221;
<h1 class="wp-block-heading">War On Mexican Drug Cartels</h1>
Maltz has long been a vocal proponent of designating Mexican drug cartels as foreign terrorist organizations, especially Mexico's <a href="https://www.benzinga.com/markets/cannabis/23/01/30614753/the-man-who-played-the-dea-el-chapos-sinaloa-cartel-us-government-on-trial-in-brooklyn">Sinaloa </a>and Jalisco cartels. &nbsp;
Hours after his inauguration, Trump did just that via <a href="https://www.whitehouse.gov/presidential-actions/2025/01/designating-cartels-and-other-organizations-as-foreign-terrorist-organizations-and-specially-designated-global-terrorists/">executive order</a>.
"The Cartels have engaged in a campaign of violence and terror throughout the Western Hemisphere that has not only destabilized countries with significant importance for our national interests but also flooded the United States with deadly drugs, violent criminals, and vicious gangs," Trump stated in the order.
Maltz sounded ready to undertake his marching orders. 
&#8220;DEA will continue to be relentless in our pursuit of the cartels who threaten this great nation," he <a href="https://www.dea.gov/press-releases/2025/01/21/career-special-agent-derek-s-maltz-appointed-lead-us-drug-enforcement">said</a>.&nbsp;
Read Also:
<ul>
<li><a href="https://www.benzinga.com/news/legal/25/01/43149460/trumps-cannabis-reform-mike-tyson-weldon-angelos-say-president-can-get-it-done">Trump&#8217;s Cannabis Reform: Mike Tyson, Weldon Angelos Say President Can Get It Done</a></li>
</ul>
Photo: Courtesy of DEA

Global

Trump Appoints DEA Chief Who Will Bring 'Ruthless Narco-Terrorists To Justice,' Not Keen On Legalizing Cannabis

<h3 class="wp-block-heading">Stocks To Buy: Cramer</h3>
On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer recommended buying Robinhood (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>).
On Jan. 13, the U.S. Securities and Exchange Commission (SEC) announced that Robinhood Securities LLC and Robinhood Financial LLC will pay a combined $45 million in civil penalties to settle a series of regulatory violations.
Cramer said Adobe Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) is a buy, adding that it has &#8220;come so far down.&#8221;
On Dec. 11, Adobe reported fourth-quarter revenue of $5.61 billion, beating the consensus estimate of $5.54 billion. The company reported fourth-quarter adjusted earnings of $4.81 per share, beating analyst estimates of $4.66 per share.
The Mad Money host said he likes Sealed Air Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEE#NYSE">SEE</a>).
Sealed Air will release its fourth quarter and full year 2024 results and 2025 outlook on Tuesday, Feb. 25.
<h3 class="wp-block-heading">Avoid This REIT Stock</h3>
Cramer recommended not buying Easterly Government Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEA#NYSE">DEA</a>).
On Dec. 6, 2024, Truist Securities analyst Michael Lewis also lowered the price target on the stock from $14 to $13.
<h3 class="wp-block-heading">Says No To This Health Care Stock</h3>
Cramer said no to IDEXX Laboratories, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>), calling it &#8220;too inconsistent.&#8221;
IDEXX Laboratories will release its 2024 fourth quarter and full year financial results on Monday, Feb. 3.
<h3 class="wp-block-heading">Other Stocks In Focus</h3>
Cramer recommended sticking with Louisiana-Pacific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPX#NYSE">LPX</a>), saying it has been a &#8220;horse&#8221; and a &#8220;great stock.&#8221;
On Jan. 8, BlueLinx and Louisiana-Pacific announced the expansion of distribution partnership.
Cramer said own Cameco Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCJ#NYSE">CCJ</a>) if you're going to own a uranium stock. However, he added, &#8220;I don't think it's a growth business.&#8221;
On Jan. 9, Cameco acknowledged the resignation of Westinghouse President and CEO.
Price Action:
<ul>
<li>Robinhood shares gained 4.5% to settle at $48.15 on Friday.</li>
<li>Louisiana-Pacific shares fell 0.6% to close at $114.91 during the session.</li>
<li>Adobe shares gained 0.7% to close at $429.99.</li>
<li>Easterly Government Properties shares gained 0.2% to settle at $11.52.</li>
<li>Cameco shares gained 4.3% to close at $51.63.</li>
<li>Sealed Air shares fell 0.5% to settle at $34.52 on Friday.</li>
<li>IDEXX Laboratories shares fell 2.2% to close at $419.26.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43089042/3m-netflix-and-3-stocks-to-watch-heading-into-tuesday">3M, Netflix And 3 Stocks To Watch Heading Into Tuesday</a></li>
</ul>
Photo: Shutterstock

Media

Trading Ideas

ADBE

HOOD

IDXX

Jim Cramer: This Tech Stock Is A Buy, Louisiana-Pacific Has Been A 'Great Stock'

The cannabis industry continues to evolve amidst regulatory challenges, expanding markets and innovative product launches. This week&#8217;s updates span U.S. federal reform delays, Florida's renewed push for legalization, international developments in Europe, corporate acquisitions and cutting-edge products reshaping the market.
<h2 class="wp-block-heading">Politics And Policy</h2>
<h4 class="wp-block-heading">DEA Hearing Postponed Amid Allegations Of Misconduct</h4>
The federal process to reclassify cannabis from Schedule I to Schedule III under the Controlled Substances Act faced a setback this week. Administrative Law Judge John Mulrooney <a href="https://www.benzinga.com/25/01/42972524/dea-judge-cancels-marijuana-rescheduling-hearing-amid-disturbing-allegations-of-improper-conduct">postponed</a> a pivotal hearing, citing allegations of misconduct within the DEA.
Advocates had accused the agency of improper communications with anti-cannabis groups and defying court orders on evidence submission. Mulrooney described the allegations as &#8220;disturbing and embarrassing,&#8221; but noted they do not irreparably taint the process. The hearing, initially scheduled for Jan. 21, will be delayed by at least three months.
This development prolongs the cannabis industry's wait for reforms that could enable tax deductions, better banking access and enhanced industry credibility.
<h4 class="wp-block-heading">Biden Grants Clemency To Thousands Of Drug Offenders</h4>
President Joe Biden <a href="https://www.benzinga.com/markets/cannabis/25/01/43054504/biden-commutes-sentences-of-nearly-2500-convicted-of-non-violent-drug-offenses-no-mention-of-cannabis-prisoners">commuted</a> the sentences of nearly 2,500 non-violent drug offenders this week, emphasizing the need to rectify sentencing disparities tied to outdated laws. However, the clemency excluded cannabis-specific prisoners, leaving advocates questioning the administration&#8217;s commitment to addressing marijuana-related convictions.
<h4 class="wp-block-heading">Florida Launches New Legalization Campaign</h4>
Following a narrow defeat in 2024, Safe &amp; Smart Florida <a href="https://www.benzinga.com/government/regulations/25/01/43018223/cannabis-legalization-headed-for-the-ballot-again-in-florida-advocates-launch-new-amendment-initiative">filed</a> a new ballot initiative to legalize recreational cannabis in 2026. The campaign, which raised over $150 million in its previous attempt, faces renewed challenges under Governor Ron DeSantis, who recently called for stricter petition signature regulations.
<h2 class="wp-block-heading">Markets And Business</h2>
<h4 class="wp-block-heading">New York Court Rules Against Warrantless Cannabis Raids</h4>
New York&#8217;s cannabis enforcement strategy faced scrutiny as a judge ruled that warrantless raids by the NYC Sheriff's Office and the Office of Cannabis Management (OCM) violated constitutional rights. Licensed hemp businesses had products seized without evidence-based testing, with the court ordering the return of goods and stricter guidelines for future inspections.
<h4 class="wp-block-heading">High Tide Enters German Medical Cannabis Market</h4>
High Tide Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HITI#NASDAQ">HITI</a>) announced its acquisition of a 51% stake in Germany-based Purecan GmbH for €4.8 million ($4.94 million). With Germany poised to become a €1 billion medical cannabis market by 2028, High Tide's move positions the company as a key supplier for Canadian imports.
<h4 class="wp-block-heading">Würk Partners With Green Check To Expand Cannabis HCM Solutions</h4>
Workforce management provider Würk partnered with Green Check to streamline compliance and analytics for cannabis operators. The collaboration aims to alleviate challenges in payroll and benefits management amidst inconsistent federal regulations.
<h4 class="wp-block-heading">Philip Morris Expands Medical Cannabis Portfolio</h4>
Philip Morris International (PMI), through its subsidiary Vectura Fertin Pharma, partnered with Avicanna (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AVCNF#OTC">AVCNF</a>) to advance cannabinoid-based medicine. The deal underscores PMI's strategic focus on medical cannabis as part of a broader shift away from tobacco.
<h2 class="wp-block-heading">Science And Research</h2>
<h4 class="wp-block-heading">CBD Does Not Impair Driving, Spanish Study Confirms</h4>
Spanish researchers found that CBD use does not impair driving performance. The study, published in &#8220;Addiction,&#8221; adds to growing evidence dispelling myths about CBD's impact on psychomotor skills, reinforcing its safety for medical and recreational use.
<h4 class="wp-block-heading">Teen Cannabis Use Drops In Legal States</h4>
A new <a href="https://www.benzinga.com/25/01/42984650/teen-marijuana-use-plummets-in-legalized-states-national-data-confirms">report</a> from the Marijuana Policy Project shows significant declines in youth cannabis use in states with adult-use legalization. In Colorado, high school cannabis consumption has dropped 42% since legalization, supporting arguments for regulated markets reducing illicit access.
<h2 class="wp-block-heading">Innovation And Product Launches</h2>
<h4 class="wp-block-heading">STIIIZY Launches Hemp-Infused Seltzers</h4>
Leading U.S. cannabis brand STIIIZY debuted its first hemp-infused seltzers, featuring four strain-inspired flavors. With 5mg of hemp-derived Delta-9 THC per can, these alcohol-free beverages cater to the growing market for cannabis-based social and lifestyle products.
<h4 class="wp-block-heading">Zone Vapor Introduces High-Tech Cannabis Vape</h4>
Zone Vapor launched the Zone Opto, a vaporizer featuring user customization modes, puff tracking and flavor control. Developed by former PAX and tobacco industry experts, the product sets a new standard for cannabis vaping technology.
<h2 class="wp-block-heading">Global Developments</h2>
<h4 class="wp-block-heading">Czechia To Regulate Low-THC Cannabis</h4>
Starting July 2025, the Czech Republic will regulate cannabis products with up to 1% THC and permit medical cannabis prescriptions through general practitioners. Advocates continue to push for broader adult-use legalization.
<h2 class="wp-block-heading">Cool Reads</h2>
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/01/43040086/nra-warns-of-legal-confusion-over-guns-and-cannabis">NRA Warns Of Legal Confusion Over Guns And Cannabis: Could Fed Ban Expand?</a></li>
<li><a href="https://www.benzinga.com/markets/cannabis/25/01/43002904/he-worked-on-producing-oxygen-on-mars-now-he-builds-cannabis-robots-the-fascinating-story-of-sorting-robotics">He Worked On Producing Oxygen On Mars, Now He Builds Cannabis Robots: The Fascinating Story Of Sorting Robotics</a></li>
<li><a href="https://www.benzinga.com/general/restaurants/25/01/42990860/large-fries-and-side-of-weed-tiktok-post-from-woman-who-got-cannabis-in-her-burger-king-order-goes-viral">Large Fries And Side Of Weed? TikTok Post From Woman Who Got Cannabis In Her Burger King Order Goes Viral</a></li>
<li><a href="https://www.benzinga.com/markets/cannabis/25/01/42979107/leonardo-davinci-meets-bungee-jumping-the-curious-origins-a-world-leading-cannabis-vaporization-brand">Leonardo DaVinci Meets Bungee Jumping: The Curious Origins Of A World-Leading Cannabis Vaporization Brand</a></li>
<li><a href="https://www.benzinga.com/markets/cannabis/25/01/42962940/this-is-how-you-make-quality-joints-how-one-machine-produces-900-pre-rolls-an-hour-and-why-theyre-better-than-cones">&#8216;This Is How You Make Quality Joints&#8217; &#8211; How One Machine Produces 900 Pre-Rolls An Hour And Why They&#8217;re Better Than Cones</a></li>
<li><a href="https://www.benzinga.com/news/legal/25/01/42957309/can-a-k-9-drug-sniffer-land-you-in-jail-for-cannabis-florida-court-sets-new-limits">Can A K-9 Drug Sniffer Land You In Jail For Cannabis? Florida Court Sets New Limits</a></li>
</ul>

Regulations

AVCNF

HITI

This Week In Cannabis: Rescheduling Delays, The DEA, Biden's Clemency, Philip Morris' New Bet And More

A new SEC filing reveals that Darrell W Crate, President &amp; CEO at Easterly Government Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEA#NYSE">DEA</a>), made a notable insider purchase on January 13,.
What Happened: Crate demonstrated confidence in Easterly Government Props by purchasing 10,000 shares, as reported in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001622194/000095017025004771//Archives/edgar/data/1622194/000095017025004771/0000950170-25-004771-index.htm">U.S. Securities and Exchange Commission</a> on Monday. The total value of the transaction is $109,100.
Tracking the Tuesday's morning session, Easterly Government Props shares are trading at $11.31, showing a down of 0.0%.
<h3>All You Need to Know About Easterly Government Props</h3>
Easterly Government Properties Inc is a real estate investment trust. It is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. The company generates all its revenue by leasing its properties to such agencies.
<h3>Easterly Government Props's Economic Impact: An Analysis</h3>
Revenue Growth: Easterly Government Props's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 3.84%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Real Estate sector.
Holistic Profitability Examination:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 66.96%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, Easterly Government Props exhibits below-average bottom-line performance with a current EPS of 0.05.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 1.12, Easterly Government Props adopts a prudent financial strategy, indicating a balanced approach to debt management.
Valuation Metrics: A Closer Look
<ul>
<li>
Price to Earnings (P/E) Ratio: The current Price to Earnings ratio of 66.53 is higher than the industry average, indicating the stock is priced at a premium level according to the market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 3.9, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Easterly Government Props's EV/EBITDA ratio, surpassing industry averages at 15.22, positions it with an above-average valuation in the market.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Activity Matters in Finance</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>Navigating the World of Insider Transaction Codes</h3>
Surveying the realm of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often give prominence to those unfolding in the open market, systematically detailed in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001622194">Check Out The Full List Of Easterly Government Props's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Insider Move: Darrell W Crate Invests $109K In Easterly Government Props Stock

A federal judge delayed a pivotal hearing on the Biden administration's <a href="https://www.benzinga.com/markets/cannabis/24/03/37552483/biden-calls-for-cannabis-reform-in-state-of-the-union-a-historic-first-no-one-should-be-jailed-f">proposal to ease restrictions on marijuana</a>, citing serious allegations of misconduct within the Drug Enforcement Administration (DEA). 
On Monday afternoon, Administrative Law Judge John Mulrooney canceled the Jan. 21 hearing, extending the process for at least three months, <a href="https://www.marijuanamoment.net/dea-judge-cancels-marijuana-rescheduling-hearings-amid-legal-challenges-pushing-back-reform-for-at-least-three-months/">according</a> to Marijuana Moment, which first reported the story.
The hearing was set to evaluate the Department of Health and Human Services&#8216; (HHS) <a href="https://www.benzinga.com/markets/cannabis/24/05/38880719/biden-announces-monumental-marijuana-rescheduling-doj-to-take-next-steps">recommendation to reclassify marijuana</a> under the Controlled Substances Act (CSA) from Schedule I, the strictest category, to Schedule III. This change could benefit the cannabis industry by allowing standard business tax deductions and improving access to banking services.
Mulrooney's decision followed a motion from cannabis policy reform advocates <a href="https://www.benzinga.com/news/legal/24/11/41923948/dea-faces-lawsuit-alleging-bias-in-marijuana-rescheduling-process">alleging improper communications</a> between DEA officials and groups opposing the proposed rule. The motion also claimed that DEA administrator <a href="https://www.benzinga.com/topic/anne-milgram">Anne Milgram</a> had unfairly selected witnesses for the hearing. While Mulrooney denied a request to remove the DEA from the proceedings, he granted leave for an interlocutory appeal, halting the hearing.
Read Also: <a href="https://www.benzinga.com/government/regulations/25/01/42882766/dea-accused-of-bias-in-cannabis-rescheduling-hearings-weed-stocks-plummeted-in-2024-as-process-drags-on">DEA Accused Of Bias In Cannabis Rescheduling Hearings: Weed Stocks Plummeted In 2024 As Process Drags On</a>
<h2 class="wp-block-heading">Judge Flags ‘Disturbing And Embarrassing' Allegations</h2>
In his ruling, Mulrooney acknowledged allegations of improper conduct, describing them as "disturbing and embarrassing." 
However, he concluded that even if true, the claims did not irreparably taint the rescheduling process. "I can no more remove or re-designate the Administrator than I can hold parties in contempt and fine them," Mulrooney said, per the outlet. "The strangeness of this unsupported approach is amplified by the fact that the appointment of a new DEA Administrator by a different political party is imminent."
The judge criticized DEA officials, stating their alleged conduct displayed "a puzzling and grotesque lack of understanding and poor judgment" in managing the rulemaking process.
<h2 class="wp-block-heading">DEA Reprimanded For Defying Evidence Submission Rules</h2>
Mulrooney also took issue with the DEA's failure to comply with his instructions regarding evidence submission. Despite being repeatedly directed to provide hard copies of evidence by Jan. 3, the agency attempted to submit thousands of public comments digitally via compact discs. Mulrooney rejected this move, calling it an "unprecedented and astonishing" act of defiance.
"The Government's deliberate disobedience of an unequivocal directive from the tribunal is unprecedented," Mulrooney said. &nbsp;
The judge ordered updates on the appeal every 90 days, ensuring no further delays in the review process. This development marks another hurdle for federal cannabis reform, reflecting ongoing challenges in navigating the bureaucratic landscape coupled with the DEA&#8217;s now obvious inclination to disrupt the process.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/news/legal/25/01/42957309/can-a-k-9-drug-sniffer-land-you-in-jail-for-cannabis-florida-court-sets-new-limits">Can A K-9 Drug Sniffer Land You In Jail For Cannabis? Florida Court Sets New Limits</a></li>
</ul>
Photo: DEA Live stream

DEA Judge Cancels Marijuana Rescheduling Hearing Amid 'Disturbing' Allegations Of Improper Conduct

The cannabis industry saw significant developments this week, with key updates from New York, New Jersey, Tilray, DoorDash, Ukraine, Agrify, Safe Harbor, the DEA and Canopy USA shaping the landscape. Here&#8217;s a closer look at the highlights.
<h3 class="wp-block-heading">New York Cannabis Industry Reports $1 Billion In 2024 Sales</h3>
New York's Office of Cannabis Management (OCM) released its 2024 annual report, showing robust growth despite a rocky start. Cannabis retailers in the state achieved nearly $1 billion in sales for 2024, supported by the issuance of 1,394 adult-use licenses, 52% of which were granted to Social and Economic Equity (SEE) applicants. The state opened 156 dispensaries, contributing over $64 million in tax revenue.
Looking ahead, the OCM aims to have 625 dispensaries operational by the end of 2025. To enhance transparency and accessibility, it launched the Legal Online Cannabis Activities Locator (LOCAL) Map, helping residents locate legal dispensaries and track license applications. However, challenges persist, including lawsuits from operators opposing recent regulatory changes and ongoing competition from unlicensed markets.
More details on <a href="https://www.cultivated.news/p/new-york-billion-cannabis-market">Cultivated</a>.
<h3 class="wp-block-heading">New Jersey Outpaces New York</h3>
Neighboring New Jersey's cannabis market reported $1 billion in sales for 2024, a 25% year-over-year increase. The Cannabis Regulatory Commission (CRC) attributed the growth to consumer trust and economic opportunities. 
"This momentum sets a solid foundation for continued success in the years ahead," <a href="https://www.cultivated.news/p/move-over-ny-nj-s-got-a-billion-dollar-cannabis-market">said</a> Chris Riggs, acting CRC director. These sales generated an estimated $43 million in tax revenue.
<h3 class="wp-block-heading">Tilray Reports Q2 2025 Financial Results</h3>
Shares of Tilray Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) traded down by double digits on Friday after the company reported its second-quarter financial results for fiscal year 2025. 
Net revenue increased by 9% to $211 million compared to $194 million in the prior year quarter, with a 10% increase on a constant currency basis. Gross profit grew 29% year-over-year to $61 million, driven by improvements across all four business segments.
Key highlights include:
<ul>
<li>Beverage alcohol revenue surged 36% to $63 million, with gross margins improving to 40%.</li>
<li>Wellness segment revenue grew 13% to $15 million.</li>
<li>International cannabis revenue increased by 25%, demonstrating Tilray's expanding global footprint.</li>
<li>Cannabis segment revenue fell slightly by 2% year-over-year to $66 million.</li>
<li>Adjusted EBITDA reached $9 million, a 10% decrease year-over-year, impacted by SKU rationalization in the beverage segment.</li>
</ul>
Tilray's Project 420, a $25 million synergy plan aimed at optimizing its beverage business, achieved $17 million in savings by the quarter's end. The company reaffirmed its fiscal year 2025 guidance, expecting net revenues between $950 million and $1 billion, ahead of consensus estimates of $900 million.
"As we enter the second half of the year, we remain committed to delivering on our financial guidance and driving shareholder value,&#8221; stated CEO Irwin Simon. &#8220;Tilray is trailblazing the future of consumer products through the infrastructure we have built, and I am enthusiastic about what lies ahead, including the potential future legalization of cannabis in the U.S."
<h3 class="wp-block-heading">DoorDash Expands Offerings To Include Hemp-Derived Products</h3>
DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) announced it is now offering hemp-derived THC and CBD products, including gummies and beverages, in select states. The expansion is facilitated through partnerships with merchants like DashMart, Total Wine &amp; More, and ABC Fine Wine &amp; Spirits.
"With the growing demand for hemp-derived THC and CBD products, we're excited to expand access to a wide selection of products consumers crave," said Jacob Morello, director and general manager of alcohol and emerging categories at DoorDash. Customers can now find a "CBD/THC" tab on the app to browse hemp-derived items in states where such products are legal.
DoorDash emphasized compliance with federal laws, ensuring all products adhere to the 2018 Farm Bill's definition of hemp, which limits THC content to 0.3% by dry weight. As part of its launch, DoorDash partnered with the cannabis beverage company Cann, offering users a $2 discount on multipack purchases through the end of January.
<h3 class="wp-block-heading">Ukraine Registers Its First Medical Cannabis Product</h3>
Ukraine has taken a significant step forward in its medical cannabis program, registering the country's first approved cannabis product. The oral cannabis drops, developed in Spain, are expected to be available in pharmacies early this year. Deputy Prime Minister Olha Stefanyshyna highlighted the progress made since the legalization of medical marijuana in 2023. "The first medicines will soon appear in pharmacies."
The law legalizes medical cannabis for patients with severe illnesses and PTSD related to the ongoing conflict with Russia. Ukraine's Ministry of Health clarified that cannabis and its derivatives are no longer listed as particularly dangerous substances, allowing for controlled medical use.
President Volodymyr Zelensky, a strong advocate for medical marijuana legalization, emphasized the importance of providing relief to Ukrainians facing pain and trauma. Training programs for doctors to treat patients with cannabis are also underway as the country expands its regulatory framework.
<h3 class="wp-block-heading">Agrify Sells Cultivation Operation for $7 Million</h3>
Agrify Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGFY#NASDAQ">AGFY</a>). has sold its cannabis cultivation operation to CP Acquisitions, an investment firm affiliated with former CEO Raymond Chang. The $7 million transaction includes vertical farming units, related assets and Agrify Insights software applications. Interim CEO Ben Kovler stated, "This move allows us to focus on more attractive growth categories tied to THC demand."
Agrify will now prioritize its hemp-derived THC beverage lines, including its popular Señorita THC-infused margaritas, which are sold in nine states and online.
<h3 class="wp-block-heading">Safe Harbor Eliminates $1.2 Million Liability</h3>
SHF Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHFS#NASDAQ">SHFS</a>), operating as Safe Harbor Financial, announced a key agreement with Partner Colorado Credit Union, eliminating $1.2 million in indemnity liability. 
CEO Sundie Seefried described the updated agreement as "a positive and pivotal development," simplifying business processes and aligning expenses with income. Safe Harbor serves more than 600 cannabis clients across 40 states and has facilitated more than $20 billion in transactions.
<h3 class="wp-block-heading">Amplify U.S. Alternative Harvest ETF To Liquidate</h3>
Amplify ETFs announced plans to liquidate its U.S. Alternative Harvest ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MJUS#NYSE">MJUS</a>), ending trading on January 27. The fund's struggles reflect broader sector challenges, including the DEA's hesitance to reschedule cannabis from Schedule I. 
Cannabis ETFs like MJUS and others saw significant declines in 2024, partly due to regulatory uncertainties and limited capital access.
<h3 class="wp-block-heading">DEA Faces Scrutiny Over Cannabis Rescheduling Process</h3>
In a new twist, a DEA judge ordered the agency to respond to allegations of bias in its cannabis rescheduling hearings. Cannabis advocates argue the DEA's late submissions and alleged coordination with anti-rescheduling groups undermine the process. The DEA's cautious stance continues to impact investor confidence and industry growth.
<h3 class="wp-block-heading">Canopy USA Appoints First President</h3>
Canopy USA, a U.S.-focused entity affiliated with Canopy Growth Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>), named Brooks Jorgensen as its first president. Jorgensen, with over 25 years of leadership experience in cannabis and other high-growth industries, aims to unify the company's portfolio of brands, including Wana, Jetty and Acreage's Superflux.
"Canopy USA is a unique platform with the right combination of ingredients to deliver success," Jorgensen stated.

AGFY

DASH

MJUS

SHF Holdings, Inc. - Class A Common Stock

SHFS

TLRY

The Week In Cannabis: Tilray Earnings, NY Hits $1B In Sales, DoorDash Embraces Hemp, Ukraine And More

Amplify ETFs announced Wednesday that it plans to liquidate the Amplify U.S. Alternative Harvest ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MJUS#NYSE">MJUS</a>), with trading set to end Jan. 27.
The Amplify U.S. Alternative Harvest ETF has a significant allocation to cannabis-related companies like Green Thumb Industries (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) and Curaleaf Holdings (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>). The fund&#8217;s price has eroded more than 50% over the last year as the cannabis sector continued to struggle with regulatory issues.
This uncertainty has weighed on cannabis stocks, as reflected in the 45% decline in the AdvisorShares Pure US Cannabis ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSOS#NYSE">MSOS</a>) in 2024.
Shareholders will receive a final cash distribution, based on the fund&#8217;s net asset value on or around Jan. 30. Amplify Investments said that it will cover all liquidation-related fees and expenses, barring brokerage fees and related costs.
Reads More: <a href="https://www.benzinga.com/government/regulations/25/01/42882766/dea-accused-of-bias-in-cannabis-rescheduling-hearings-weed-stocks-plummeted-in-2024-as-pro">DEA Accused Of Bias In Cannabis Rescheduling Hearings: Weed Stocks Plummeted In 2024 As Process Drags On</a>
<h3 class="wp-block-heading">Regulatory Roadblocks Stifle Growth</h3>
A key reason behind the unsteadiness in the cannabis industry — and funds like MJUS — is the <a href="https://www.benzinga.com/markets/cannabis/24/06/39277690/dea-vs-biden-fda-health-agency-over-cannabis-rescheduling-whats-up-with-that">Drug Enforcement Administration&#8217;s role </a>in maintaining marijuana&#8217;s classification as a Schedule I drug under the Controlled Substances Act, a categorization reserved for substances with no medical use and a high potential for abuse. This has led to limitations on research, banking and taxation for cannabis businesses.
Although the U.S. Department of Health and Human Services <a href="https://www.benzinga.com/markets/cannabis/24/01/36620822/feds-finally-release-documents-confirming-recommendation-to-reschedule-cannabis-based-on-accepte">recommended rescheduling marijuana</a> to Schedule III, which would ease some federal restrictions, the DEA has the final say. The agency's cautious stance on cannabis rescheduling and the uncertainty around the decision is impacting investor confidence.
<h3 class="wp-block-heading">Broader Impact on Cannabis ETFs</h3>
MJUS is not alone in facing these challenges. ETFs with high exposure to cannabis stocks are also struggling from weak financial performance to limited capital access. The DEA's lack of action has left cannabis firms, and the funds that track them, vulnerable. Funds like AdvisorShares Vice ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VICE#NYSE">VICE</a>), Cambria Cannabis ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/TOKE#BATS">TOKE</a>) and Roundhill Cannabis ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/WEED#BATS">WEED</a>) did not have their best year in 2024.
See Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42793407/cannabis-physician-surgeon-generals-alcohol-cancer-risk-warning-is-a-wake-up-call">EXCLUSIVE: Cannabis Physician Says Surgeon General's Alcohol Cancer Risk Warning Is ‘Wake-Up Call'</a></li>
</ul>
Photo: Shutterstock

Specialty ETFs

ETFs

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

MSOS

TOKE

VICE

WEED

Amplify To Liquidate Cannabis-Focused MJUS ETF As Regulatory Uncertainty Weighs On Sector

In a new twist on Wednesday, a DEA judge ordered the agency to respond to allegations that it opposes President Joe Biden's <a href="https://www.benzinga.com/markets/cannabis/23/08/34126690/hhs-secretary-confirms-it-is-recommending-cannabis-be-rescheduled-per-bidens-directive">directive of August 2023 to reschedule marijuana</a> and that it is improperly conferring with cannabis opponents. 
Marijuana Moment <a href="https://www.marijuanamoment.net/dea-judge-orders-agency-to-respond-to-new-allegations-it-opposes-marijuana-rescheduling-and-improperly-conspired-with-prohibitionists/">reported</a> that one day after a motion was filed outlining these allegations, which include improper communications with opponents of the reform, the DEA is now compelled to reply next week. Additionally, participants in the hearings are asking the judge to remove the DEA from the process, noted the outlet.
DEA Administrative Law Judge John Mulrooney <a href="https://www.dea.gov/sites/default/files/2025-01/Marijuana%20Rescheduling_Ord%20re%20Mot%20for%20Recon%20Response%20%28e%29.pdf">wrote</a> that the government is ordered to file a response to a motion to reconsider by Jan. 13. 
What Happened: Attorneys representing cannabis advocates argued the DEA&#8217;s late submission of data on marijuana reclassification undermines the fairness of the hearing process. 
They said the agency violated federal law by withholding information until the eve of the hearing, hindering the Department of Health and Human Services <a href="https://www.benzinga.com/markets/cannabis/24/01/36620822/feds-finally-release-documents-confirming-recommendation-to-reschedule-cannabis-based-on-accepte">scientific review of January 2024 </a>and depriving pro-rescheduling groups of a fair opportunity to participate.
Adding fuel to the fire, <a href="https://www.benzinga.com/markets/cannabis/24/03/37603576/dea-vs-white-house-agency-pushes-back-on-medical-benefits-of-cannabis-weed-stocks-wobble">statements from the DEA</a> have questioned the medical value of cannabis, citing a lack of robust clinical trials approved by the Food and Drug Administration to support the safety and efficacy of cannabis for its various therapeutic uses.
The original motion regarding &#8220;ex parte&#8221; communications included failing to disclose nearly 100 requests to participate in the hearings and coordinating<a href="https://www.benzinga.com/24/11/42144540/dea-slammed-over-unlawful-talks-with-cannabis-opponents-the-plot-thickens"> with at least one anti-rescheduling group</a>.
Read Also: <a href="https://www.benzinga.com/24/11/42144540/dea-slammed-over-unlawful-talks-with-cannabis-opponents-the-plot-thickens">DEA Slammed For Unlawful Talks With Cannabis Opponents &#8211; The Plot Thickens</a>
<h2 class="wp-block-heading">Cannabis Stocks: Deep Declines Over The Year</h2>
The reclassification process, the first of its kind since 1970, has kept cannabis industry and marijuana stocks on edge and it showed at the end of 2024. 
AdvisorShares Pure US Cannabis ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSOS#NYSE">MSOS</a>), a benchmark for the sector, plummeted by about 48% in 2024. As of this writing, MSOS shares are down 5.91% on the day. 
U.S. and Canadian marijuana stocks didn't do much better amid concerns over the outcome of the DEA&#8217;s review.
Curaleaf Holdings (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>) fell some 62% in 2024. Verano Holdings (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VRNOF#OTC">VRNOF</a>) lost about 73%, Trulieve (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>) fell about 7.5%, Green Thumb Industries (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) is down 31% and Cresco Labs (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>) has lost about 37% of its value. TerrAscend (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TSNDF#OTC">TSNDF</a>) was also down by 62% in 2024, while Ascend Wellness (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AAWH#OTC">AAWH</a>) dropped 64%.
Canopy Growth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) has fallen 45% and Tilray Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) subtracted 37%. One exception was Canada&#8217;s OrganiGram (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>), which rose more than 20%.
The DEA is required to respond to the allegations by Jan. 13, so stay tuned as the process grinds on.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/25/01/42805558/from-prison-to-profits-heres-how-this-entrepreneurs-cannabis-business-makes-800000-monthly">From Prison To Profits: Here&#8217;s How This Entrepreneur&#8217;s Cannabis Business Makes $800,000 Monthly</a></li>
</ul>
Image AI created.

Equities

Small Cap

Movers

AAWH

CRLBF

TCNNF

TSNDF

VRNOF

DEA Accused Of Bias In Cannabis Rescheduling Hearings: Weed Stocks Plummeted In 2024 As Process Drags On

In 2024, the cannabis landscape in the United States experienced some developments, though federal legalization or removal from the <a href="https://www.benzinga.com/topic/controlled-substances-act">Controlled Substances Act</a> (CSA) did not occur under the Biden administration, though that was <a href="https://www.benzinga.com/markets/cannabis/24/11/41752800/kamala-harris-promises-to-legalize-recreational-marijuana-in-groundbreaking-instagram-post">promised to voters</a> on a regular basis.
&#8220;No one should be in jail for cannabis possession&#8221; was the refrain repeated by President <a href="https://www.benzinga.com/topic/joe-biden">Joe Biden</a>, beginning with his March 2024 <a href="https://www.benzinga.com/markets/cannabis/24/03/37552483/biden-calls-for-cannabis-reform-in-state-of-the-union-a-historic-first-no-one-should-be-jailed-f">State of the Union</a> — the first time marijuana was ever mentioned in such an illustrious political setting — all the way up to his mid-December 2024 <a href="https://www.benzinga.com/news/legal/24/12/42466804/biden-commutes-1500-sentences-grants-39-pardons-pot-prisoners-included-marks-single-day-record?adt_ei=%7b%7bemail%7d%7d&amp;he=%7b%7bemail%7d%7d">commutation of 1500 people</a> including a relatively small number of cannabis offenders.
<h2 class="wp-block-heading">Federal Rescheduling? Delay And More Delay</h2>
The Drug Enforcement Administration (DEA) <a href="https://www.benzinga.com/markets/cannabis/24/05/38920897/infographic-deas-proposed-rules-for-marijuana-what-you-need-to-know">initiated a review </a>to reclassify cannabis from a Schedule I to a Schedule III substance under the CSA. This move, following the August 2023 Biden-directed <a href="https://www.benzinga.com/markets/cannabis/23/08/34126690/hhs-secretary-confirms-it-is-recommending-cannabis-be-rescheduled-per-bidens-directive">recommendations</a> from the Department of Health and Human Services, could have represented a historic shift in federal cannabis policy. But alas, it was never finalized. The move would have alleviated challenges related to taxation and research restrictions faced by the industry under the ongoing federal restrictions.
<h2 class="wp-block-heading">Congress, Where Are You?</h2>
Rep. <a href="https://www.benzinga.com/topic/earl-blumenauer">Earl Blumenauer</a> (D-OR), longtime cannabis reform advocate, said in a mid-December <a href="https://www.c-span.org/clip/public-affairs-event/user-clip-blumenauer-exit-interview-cannabis-legacy/5147106">C-Span interview</a> that Congress seems to be "trapped in time."
"My work on cannabis legalization and working to end the failed war on drugs is one of my greatest areas of satisfaction and one of my greatest disappointments," said Blumenauer who has been involved in cannabis reform since 1973 when he was an Oregon state legislator.
The incoming GOP-led Congress, at least so far, has not prioritized cannabis reform, thus diminishing prospects for supportive legislation.
Read Also: <a href="https://www.benzinga.com/news/legal/24/12/42704814/guns-and-cannabis-dont-mix-in-kentucky-medical-marijuana-law-takes-effect-on-new-years-day">Guns And Cannabis Don&#8217;t Mix In Kentucky: Medical Marijuana Law Takes Effect On New Year&#8217;s Day</a>
<h2 class="wp-block-heading">But There Were State-Level Legalization Initiatives</h2>
Several states presented cannabis-related measures during the November 2024 elections with mixed outcomes.
<ul>
<li>Nebraska: Voters <a href="https://www.benzinga.com/markets/cannabis/24/11/41764503/nebraska-says-yes-to-medical-cannabis-after-years-of-failed-legalization-attempts-heres-what-you">approved the legalization of medical cannabis</a>, marking a significant policy change in a state where cannabis was previously entirely illegal.</li>
<li>Florida: A well-funded campaign to legalize recreational marijuana <a href="https://www.benzinga.com/markets/cannabis/24/11/41763514/florida-rejects-cannabis-legalization-amendment-supported-by-trump-detested-by-desantis">failed to achieve</a> the required 60% supermajority, despite substantial financial backing and public support.</li>
<li>North Dakota and South Dakota: Both states <a href="https://www.benzinga.com/markets/cannabis/24/11/41765421/south-dakota-rejects-measure-29-cannabis-legalization-fails-again">rejected measures</a> to legalize recreational marijuana, reflecting ongoing resistance in certain regions.</li>
</ul>
<h2 class="wp-block-heading">How Did Market Dynamics Fair?</h2>
The cannabis market faced economic challenges throughout 2024, with many U.S. and Canadian companies experiencing significant <a href="https://www.benzinga.com/markets/cannabis/24/11/41793174/cannabis-stocks-collapse-after-trump-win-major-players-see-double-digit-declines-at-wednesdays-c">stock price declines</a>. Factors contributing to this downturn included regulatory uncertainties, taxation issues and competition from rampant illicit markets. 
Notably, AdvisorShares Pure US Cannabis ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSOS#NYSE">MSOS</a>) experienced a challenging 2024, with its stock price declining by approximately 48%, <a href="https://www.benzinga.com/quote/MSOS">noted</a> Benzinga PRO, indicating broader market struggles including the aforementioned regulatory challenges.
<h2 class="wp-block-heading">Public Perception And Usage – Some Positive News</h2>
Marijuana&#8217;s popularity continued to rise, with daily users in the U.S. <a href="https://www.benzinga.com/markets/cannabis/24/05/38976556/daily-cannabis-consumption-outpaces-daily-alcohol-use-in-the-us-for-the-first-time-new-study-sho">surpassing alcohol consumers</a>. 
This shift is attributed to changing legal statuses, increased public awareness of marijuana&#8217;s health benefits and the general acceptance of marijuana as a benign substance, the consumption of which has never resulted in any reported deaths. 
Now we just need a bit more support for rescheduling and maybe even legalization.
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42690082/trump-is-first-republican-president-with-a-pathway-to-cannabis-reform-says-former-adviser">Trump Is First &#8216;Republican President&#8217; With A Pathway To Cannabis Reform, Says Former Adviser</a></li>
</ul>
Image: Shutterstock

Sector ETFs

Cannabis Reform 2024: The Year Of All Talk And No Action

A significant insider buy by Darrell W Crate, President &amp; CEO at Easterly Government Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEA#NYSE">DEA</a>), was executed on December 23, and reported in the recent SEC filing.
What Happened: In a recent Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001622194/000095017024139497//Archives/edgar/data/1622194/000095017024139497/0000950170-24-139497-index.htm">U.S. Securities and Exchange Commission</a> on Monday, Crate increased their investment in Easterly Government Props by purchasing 10,000 shares through open-market transactions, signaling confidence in the company's potential. The total transaction value is $109,100.
The latest update on Tuesday morning shows Easterly Government Props shares up by 0.54%, trading at $11.1.
<h3>Get to Know Easterly Government Props Better</h3>
Easterly Government Properties Inc is a real estate investment trust. It is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. The company generates all its revenue by leasing its properties to such agencies.
<h3>A Deep Dive into Easterly Government Props's Financials</h3>
Revenue Growth: Over the 3 months period, Easterly Government Props showcased positive performance, achieving a revenue growth rate of 3.84% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Real Estate sector.
Holistic Profitability Examination:
<ul>
<li>
Gross Margin: Achieving a high gross margin of 66.96%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): Easterly Government Props's EPS reflects a decline, falling below the industry average with a current EPS of 0.05.
</li>
</ul>
Debt Management: Easterly Government Props's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.12.
Valuation Analysis:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a higher-than-average P/E ratio of 64.94, Easterly Government Props's stock is perceived as being overvalued in the market.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 3.8, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio of 15.06, the company's market valuation exceeds industry averages.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Illuminating the Importance of Insider Transactions</h3>
Considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>Deciphering Transaction Codes in Insider Filings</h3>
When analyzing transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001622194">Check Out The Full List Of Easterly Government Props's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

U.S. authorities are reportedly investigating Chinese router manufacturer TP-Link as a possible threat to national security after multiple cyberattacks have been linked to the <a href="https://www.benzinga.com/content/42521121/tp-link-archer-gxe75-with-wtfast-integration-now-available-on-amazon-in-the-usa">company's popular routers.</a>
What To Know: TP-Link is the top seller of routers on Amazon and holds about 65% of the U.S. market share of commercial and residential routers, speaking to the widespread use of the manufacturer's equipment, according to a Wall Street Journal <a href="https://www.wsj.com/politics/national-security/us-ban-china-router-tp-link-systems-7d7507e6?mod=hp_lead_pos1">report</a>. 
According to the Wall Street Journal's sources, three U.S. government departments — Commerce, Defense and Justice — opened probes into the company.&nbsp;&nbsp;
An office of the Department of Commerce subpoenaed TP-Link and the Department of Justice is investigating whether the company is violating a law against attempting a monopoly by selling products for less than cost, according to a person familiar with the matter. Earlier this year, the Department of Defence opened an investigation into national-security vulnerabilities in Chinese routers, according to people familiar with the matter, per the Wall Street Journal. 
Authorities could ban TP-Link routers in the U.S. as soon as next year, according to people familiar with the matter, the Journal said. 
Benzinga contacted Amazon and TP-Link to comment on the report and has not received a response at the time of publication.&nbsp;
Read Next: <a href="https://www.benzinga.com/general/market-summary/24/12/42535400/americans-bought-less-but-paid-more-says-peter-schiff-experts-digest-november-retail-sales-data">&#8216;Americans Bought Less But Paid More,&#8217; Says Peter Schiff: Experts Digest November Retail Sales Data</a>
TP-Link&#8217;s Aginet brand<a href="https://www.tp-link.com/us/press/news/20443/"> gained </a>significant traction with over 300 ISPs including AT&amp;T, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>), Comcast Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) and Verizon Communications Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) choosing TP-Link as a supplier.&nbsp;
TP-Link routers are also used by the Department of Defense, National Aeronautics and Space Administration, Drug Enforcement Agency and other federal agencies, highlighting the potential risk of national-security vulnerabilities related to the Chinese routers. 
Why It Matters: If TP-Link routers are banned, it would mark the largest ban on Chinese technology in the U.S. since the Trump administration in 2019 prohibited equipment from Huawei Technologies. The Biden administration initiated probes into TP-Link, but any actions to be taken against the company will likely fall to the incoming Trump administration.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42515463/nike-needs-a-turnaround-after-q2-results-are-released-this-week-will-new-ceo-just-do-it">Nike Needs A Turnaround After Q2 Results Are Released This Week: Will New CEO &#8216;Just Do It?&#8217;</a></li>
</ul>
Photo: Shutterstock

Tech

CMCSA

Trump Administration Could Ban Amazon's Top-Selling Routers Linked To Chinese Cyberattacks: Report

The long-awaited hearing to discuss <a href="https://www.benzinga.com/topic/cannabis-rescheduling">cannabis rescheduling</a> will begin on January 21, 2025, marking a significant moment in the ongoing debate over cannabis regulation. As Business of Cannabis <a href="https://businessofcannabis.com/cannabis-rescheduling-hearing-set-to-begin-on-january-21-for-6-weeks-as-frustrations-over-process-continue-to-build/">reported</a>, the six-week hearing will continue until March 6, 2025, but its outcome remains uncertain due to political and procedural challenges.
With key positions in the new administration still unconfirmed, many questions remain about how much influence the incoming cabinet will have on the hearings. This uncertainty has raised concerns over the DEA&#8217;s impartiality and the fairness of the process.
<h3 class="wp-block-heading">Legal Challenges From Health Coalitions And Advocates</h3>
In a move that has added to the controversy, the Doctors for Drug Policy Reform has filed a federal court petition challenging the DEA's exclusion from the hearings. According to Businnes of Cannabis, the group argues that their medical expertise is essential for evaluating the implications of cannabis rescheduling, particularly regarding medical marijuana prescriptions.
Additionally, weeks ago, the agency <a href="https://www.benzinga.com/markets/cannabis/24/11/42169153/dea-judge-blocks-researchers-motion-in-cannabis-rescheduling-case">denied MedPharm's bid to join the December 2 hearing</a>. MedPharm, a DEA-registered research firm, criticized the exclusion of marijuana researchers and the inclusion of prohibitionist organizations such as Smart Approaches to Marijuana (SAM).&nbsp;
SAM has been also at the center of the controversy. On November 28, attorney Matt Zorn <a href="https://www.benzinga.com/24/12/42274698/dea-sued-for-allegedly-hiding-emails-with-anti-marijuana-group">sued the DEA</a> for failing to release records related to its communications with the organization. The DEA dismissed them as "gossip," arguing that there was no illegal contact, despite SAM President Kevin Sabet admitting to discussing the details of the rescheduling with DEA insiders. <a href="https://www.benzinga.com/government/regulations/24/11/42198793/prohibitionist-group-denies-collusion-allegations-ahead-of-dea-cannabis-rescheduling-hearing">SAM also denied</a> that the conversations had anything to do with the rescheduling procedure.
Earlier in November, the Veterans Action Council, a cannabis advocacy organization for military veterans, <a href="https://www.benzinga.com/news/legal/24/11/42068859/veterans-group-challenges-dea-for-seat-at-cannabis-debate-table">filed a petition</a> challenging its exclusion from the DEA&#8217;s participant list, published in October. The petiton followed the withdrawal of some designated participants and growing scrutiny over the agency's handling of the rescheduling process.
Several organizations have pulled out of the hearings since the initial announcement. The American College of Occupational and Environmental Medicine missed important procedural deadlines, while an oncologist representing the American Academy of Hospice and Palliative Medicine opted not to participate. Additionally, five remaining participants are represented by David Evans, a prominent anti-cannabis advocate, highlighting the polarized nature of the upcoming hearings.
<h3 class="wp-block-heading">Scheduled Presentations And Participants</h3>
The DEA has outlined a strict schedule for the hearings, featuring presentations from various stakeholders, including industry groups, law enforcement and medical professionals. Notable participants include the National Cannabis Industry Association and Smart Approaches to Marijuana, among others. The schedule includes:
<ul>
<li>January 21: Presentation by the government</li>
<li>January 22-23: Presentations from Hemp for Victory, Cannabis Bioscience International Holdings and other groups</li>
<li>January 28-30: Presentations from the Connecticut Office of the Cannabis Ombudsman, National Cannabis Industry Association and additional participants</li>
<li>February 4-6: Presentations from The Commonwealth Project, Veterans Initiative 22 and others</li>
<li>February 18-20: Presentations from the Tennessee Bureau of Investigation, International Association of Chiefs of Police and more</li>
<li>February 25-27: Presentations from Smart Approaches to Marijuana, Community Anti-Drug Coalitions of America and other stakeholders</li>
<li>March 4-6: Presentations from Dr. Kenneth Finn, National Drug and Alcohol Screening Association and others.</li>
</ul>
<h3 class="wp-block-heading">Public Comments Excluded From the Process</h3>
Although more than <a href="http://v">43,000 public comments were submitted</a> during the 60-day comment period, the DEA has ruled that these comments will not be accepted as evidence, citing the limitations of the Administrative Procedure Act. This decision has generated criticism from cannabis advocates and industry leaders.
<h3 class="wp-block-heading">High Stakes For The Industry</h3>
Reclassifying marijuana could provide <a href="https://www.benzinga.com/markets/cannabis/24/05/38901900/what-schedule-iii-really-means-for-cannabis-industry-and-consumers-congressional-experts-explain">significant advantages to the U.S. cannabis industry</a>. It would ease research and financial restrictions, improve access to banking and reduce legal challenges, enabling businesses to operate more freely. A Schedule III classification could also lead to broader insurance coverage and more federal funding for cannabis research, potentially fostering growth, investment and innovation. Advocates argue that rescheduling would enhance regulation and increase access to medical cannabis, but given the complexities of the process, the final decision may still be months away, with lasting impacts on the industry.
Cover image made with AI

DEA's Cannabis Rescheduling Hearing Set To Begin In January 2025 As Controversy Mounts

Truist Securities analyst Michael Lewis maintains Easterly Government Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEA#NYSE">DEA</a>) with a Hold and lowers the price target from $14 to $13.

Price Target

Analyst Ratings

Truist Securities Maintains Hold on Easterly Government Props, Lowers Price Target to $13

President-elect Donald Trump said Wednesday that he himself pulled out his initial pick to lead the Drug Enforcement Agency (DEA) despite the fact that Florida Sheriff Chad Chronister <a href="https://www.benzinga.com/news/legal/24/12/42306303/trumps-dea-pick-withdraws-from-consideration-will-keep-job-as-florida-sheriff">announced the day before</a> that he was withdrawing from consideration.
Nevertheless, Trump took to the airwaves insisting that Chronister did not pull out, but rather it was the other way around.
<h2 class="wp-block-heading">Then He Shot The Messenger</h2>
"The Wall Street Journal is becoming more and more obnoxious and unreadable. Today's main headline is: ‘Trump's DEA Pick Pulls Out In Latest Setback.' With all that's happening in the World, this is their Number One story of the day," Trump <a href="https://truthsocial.com/@realDonaldTrump/posts/113595507414156033">wrote</a> on Truth Social.
"Besides, he didn't pull out, I pulled him out, because I did not like what he said to my pastors and other supporters. But, more importantly, what's my &#8216;latest&#8217; setback???'"
<h2 class="wp-block-heading">Trump&#8217;s Pastors?</h2>
Trump was referring to an incident from back in the dark days of the pandemic when Chronister announced the arrest of a Tampa church pastor for having conducted a service during the height of social distancing. Though the charges were ultimately dropped, Florida's right-wing anti-maskers went on a rampage against Chronister at the time.
When Chronister said no to the Trump DEA job offer, he didn't mention the conservative backlash that was bubbling up mostly in Florida, although some out-of-staters jumped in to give him hell. "This sheriff ordered the arrest of a pastor for holding services during the COVID panic. Glad to see him withdraw from consideration," Rep. Thomas Massie (R-Ky) <a href="https://x.com/RepThomasMassie/status/1864073791283826739">posted</a> on X. "Next time politicians lose their ever-lovin minds, he can redeem himself by following the Constitution.&#8221;
<h2 class="wp-block-heading">Did Someone Get His Feelings Hurt?</h2>
When he initially picked Chronister to head up the DEA, Trump <a href="https://truthsocial.com/@realDonaldTrump/posts/113574561799756610">sang his praises</a>, saying the sheriff would succeed in stopping "the flow of Fentanyl, and other Illegal Drugs, across the Southern Border, and SAVE LIVES."
Is Trump feeling jilted? That could be, but we'll never know. The President-elect has valiantly chosen to move on. As for who will lead the DEA, we'll just have to wait. There surely are hundreds waiting in the wings (and the halls of Fox News), in the hope of getting the tweet that'll change his/her life.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42349036/us-taxpayer-funds-global-drug-war-leaving-evidence-based-health-responses-behind">$13-Billion Drug War Funded By U.S. Taxpayers Fuels Violence In Developing Countries: New Report</a></li>
</ul>

Trump's DEA Drama: He Didn't Quit, I Fired Him — A Tale Of Pastors, Pandemic And Hurt Feelings

Since 2015, U.S. taxpayers have allocated nearly $13 billion to international &#8220;counternarcotics&#8221; activities, including law enforcement, military support and punitive drug policies.&nbsp;
According to a report by Harm Reduction International (HRI) and the Drug Policy Alliance (DPA), this spending has prioritized drug control over evidence-based health responses, often leading to severe human rights abuses and undermining global development goals.
<h3 class="wp-block-heading">U.S. Taxpayer Funding Global Drug War</h3>
The U.S. government's role in <a href="https://www.benzinga.com/markets/cannabis/23/04/32053616/Waiting-to-Inhale">funding the global war on drugs</a> is unparalleled, spanning multiple government agencies, <a href="https://www.benzinga.com/markets/cannabis/23/10/35350765/deas-50-year-1-trillion-drug-war-why-were-there-250k-marijuana-arrests-in-2022">including the DEA</a>, the Department of State and USAID. While $13 billion was channeled into international narcotics control programs over the past decade, this funding exceeds U.S. foreign aid for essential services like primary education, water supply, sanitation and women's rights combined. 
HRI and DPA's <a href="https://drugpolicy.org/wp-content/uploads/2024/11/A-World-of-Harm-Report-FINAL-11_25.pdf">report</a>, titled "A World of Harm", shows how this prioritization of punitive measures over health-based responses has resulted in rising human rights violations, including forced rehabilitation programs, displacement and criminalization.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">U.S. assistance has supported and expanded destructive and deadly anti-drug responses around the world. Our new report shows how U.S. taxpayers fund the global war on drugs over evidence-based health responses: <a href="https://t.co/wb8ykE5AdE">https://t.co/wb8ykE5AdE</a> <a href="https://t.co/oEM5kQQ5lj">pic.twitter.com/oEM5kQQ5lj</a>
&mdash; Harm Reduction International (@HRInews) <a href="https://twitter.com/HRInews/status/1864339450567839864?ref_src=twsrc%5Etfw">December 4, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</li>
</ul>
Notably, the report highlights three key countries— the Philippines, Colombia and Mexico— where U.S. taxpayer funds have directly supported controversial narcotics control programs, often with devastating consequences.
<h3 class="wp-block-heading">Coerced Rehabilitation Backed By U.S. Funds</h3>
In the Philippines, the U.S. has funded &#8220;forced rehabilitation&#8221; programs, despite <a href="https://filtermag.org/coerced-drug-treatment-harms/">growing evidence</a> that such approaches harm individuals more than they help. As the country's war on drugs escalated under former President Duterte, U.S. funding supported the government&#8217;s crackdown, contributing to extrajudicial killings and human rights abuses.
&#8220;There are no voluntary community-based programs,&#8221; stated civil society advocates in the report, adding that most individuals in these programs are coerced.
<h3 class="wp-block-heading">U.S. Corporations Profit From Toxic Fumigation</h3>
In Colombia, U.S. funds helped bankroll aerial fumigation campaigns targeting coca crops, often destroying food crops in the process. The toxic chemicals used in these campaigns have been <a href="https://www.benzinga.com/markets/cannabis/23/10/35170036/unseen-damage-how-the-war-on-drugs-accelerates-climate-crisis-new-report">linked to environmental degradation</a> and health problems, including skin disorders and miscarriages.&nbsp;
Read More: <a href="https://www.benzinga.com/markets/cannabis/23/09/34700973/colombian-cocaine-nears-oil-revenue-war-on-drugs-failure-and-rural-inequality-amplify-the-equati">Colombian Cocaine Nears Oil Revenue: War On Drugs Failure And Rural Inequality Amplify The Equation</a>
Moreover, the report underscores how U.S. assistance to Colombian law enforcement has disproportionately benefited private U.S. corporations, such as Dyncorp, which carried out the fumigation operations.
<h3 class="wp-block-heading">Drug War Militarization Increases Violence, Femicide Rates</h3>
Similarly, in Mexico, U.S. support for the drug war has fueled militarization, leading to record levels of drug-related violence. The U.S. has spent millions in Mexico on law enforcement, yet the <a href="https://www.benzinga.com/markets/cannabis/24/07/39672021/un-exposes-mexicos-dominance-as-a-global-meth-and-fentanyl-producer">funding has failed to curb drug trafficking or reduce violence</a>. Instead, it has exacerbated issues like femicide and repression against civil society.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/42225423/mexico-president-claudia-sheinbaum-to-trump-neither-threats-nor-tariffs-will-solve-your-fentanyl-crisis">Mexico President Claudia Sheinbaum To Trump: &#8216;Neither Threats Nor Tariffs&#8217; Will Solve Your Fentanyl Crisis</a>
<h3 class="wp-block-heading">Call For Reorientation Of U.S. International Aid</h3>
Despite some positive shifts in U.S. domestic drug policy, such as <a href="https://www.benzinga.com/general/health-care/24/11/42146502/us-overdose-deaths-decline-as-fentanyl-potency-weakens-harm-reduction-expands">expanding harm reduction services</a>, international aid continues to reinforce a punitive approach.
The report calls for a reorientation of U.S. foreign aid from militarized enforcement strategies toward <a href="https://www.benzinga.com/markets/cannabis/24/06/39470316/un-health-officials-new-report-calls-for-end-to-drug-war-harm-reduction-scientific-approach-to-d">evidence-based harm reduction programs</a>. These responses would not only support the rights and well-being of people who use drugs but also address critical public health and development challenges in affected countries.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42325714/medical-marijuana-patient-from-canada-is-facing-a-life-sentence-in-a-dubai-prison-over-his-medicine">Canadian Citizen Sentenced To Life In Dubai Prison For Possession Of Medical Marijuana</a></li>
</ul>

$13-Billion Drug War Funded By U.S. Taxpayers Fuels Violence In Developing Countries: New Report

In a recent note, senior analyst Pablo Zuanic digs into the financial standing and valuation of Village Farms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>), the <a href="https://www.benzinga.com/markets/cannabis/24/11/41726679/village-farms-is-only-cannabis-operator-selected-to-represent-weed-industry-at-dea-rescheduling-">only cannabis company </a>anointed by the Drug Enforcement Agency (DEA) as one of the 25 DPs ("designated participants") in the <a href="https://www.benzinga.com/24/12/42270539/dea-live-hearing-on-marijuana-rescheduling-what-to-expect">administrative hearing</a> for the rescheduling of cannabis to Schedule III.
According to Zuanic, the company experienced temporary sales disruptions in the second half of the year, primarily due to stockouts caused by strong first-half demand. These disruptions are expected to normalize by the first quarter of 2025. Although the overall demand for Canadian recreational cannabis is <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41599546/canadas-cannabis-market-goes-cold-pot-prices-hit-bottom-why-top-producers-are-losin">slowing down</a>, Village Farms has been able to increase prices for some SKUs.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can't afford to miss out if you&#8217;re serious about the business.</li>
</ul>
<h3 class="wp-block-heading">Global Reach And Scale</h3>
Beyond Canada, Village Farms is focused on growing its international business, particularly in Germany, <a href="https://www.benzinga.com/topic/australia-cannabis">Australia</a>, and the UK. It plans to allocate Canadian production based on return on investment (ROI) and may consider minority investments in <a href="https://www.benzinga.com/general/market-summary/24/11/42126680/german-cannabis-20-tons-10m-grams-and-thats-only-0-3-of-the-market-whats-missing">international markets</a>.
The company will prioritize its branded domestic cannabis business and<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39609582/europe-is-turning-cash-flow-positive-well-see-what-happens-in-the-u-s-largest-canna"> international sales</a>. It will reduce B2B sales for domestic purposes and allocate more output to its branded products.
Branded sales margins are recovering to the 30-40% range and B2B margins are increasing due to higher prices and increased overseas demand. Zuanic noted approximately one-third of domestic B2B sales are re-exported to <a href="https://www.benzinga.com/topic/germany-cannabis">Germany</a>.
Read Also:<a href="https://www.benzinga.com/government/regulations/24/11/42198793/prohibitionist-group-denies-collusion-allegations-ahead-of-dea-cannabis-rescheduling-hearing"> Prohibitionist Group Denies Collusion Allegations Ahead Of DEA Cannabis Rescheduling Hearing</a>
<h3 class="wp-block-heading">Market Share </h3>
Hifyre data for October and November shows a sequential improvement in the Canadian recreational cannabis market, with a year-over-year growth of 6.7%. However, Village Farms experienced a deceleration to 1% year-over-year growth.
<ul>
<li>Among the top 10 players, Tilray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) (-21%), Decibel (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DBCCF#OTC">DBCCF</a>) (-23%), and Canopy Growth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) (-21%) experienced a decline in growth. On the other hand, Cannara (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LOVFF#OTC">LOVFF</a>) (+67%) and WeedMD (+23%) saw significant growth.&nbsp;</li>
<li>OGI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) (+13%), Auxly (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) (+33%), Motif (+10%), and Cronos Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRON#NASDAQ">CRON</a>) (+4%) also exhibited positive growth.</li>
<li>In terms of November market share, Tilray (TLRY) (9.1%) held the largest share, followed by OGI (7.0%), VFF (6.2%), Auxly (5.6%), Motif (5.3%), Cronos Group (5.1%), Decibel (4.7%), Cannara (4.0%), WeedMD (2.9%), and Canopy Growth (2.3%).</li>
</ul>
Read Also:<a href="https://www.benzinga.com/markets/cannabis/24/11/41805907/village-farms-quarterly-revenue-grows-20-yoy-as-the-cannabis-company-doubles-international-sales"> Village Farms Quarterly Revenue Grows 20% YoY As The Cannabis Company Doubles International Sales</a>
<h3 class="wp-block-heading">Valuation </h3>
Zuanic<a href="https://zuanicgroup.com/"> argues</a> that Village Farms' stock is undervalued due to its complex business model and gradual growth strategy, despite its strong performance in the Canadian cannabis market, international expansion and potential US opportunities. 
He calculates the company&#8217;s enterprise value (EV) to be around US$120 million. This valuation implies a low multiple of 0.4x current sales estimates and 5.6x EBITDA.
Zuanic says the market is not fully recognizing the value of VFF&#8217;s assets. 
If we strip out the value of the produce business, US CBD operations and <a href="https://www.benzinga.com/topic/texas-cannabis">Texas</a> greenhouses, Zuanic suggests that the remaining valuation for the cannabis unit is around US$19 million, or 0.1x estimated 2025 sales and 3x EBITDA. This is significantly lower than the<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41811378/aurora-vs-canopy-tilray-which-nasdaq-listed-cannabis-stock-offers-the-best-growth-p"> valuations of other major cannabis companies</a> like <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41613366/beyond-beer-tilrays-1-67-billion-market-play-is-this-cannabis-giant-still-a-smart-b">Tilray</a> and Aurora Cannabis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>).
Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41925770/three-paths-to-cannabis-profits-village-farms-green-thumb-and-jushi-show-divergent-">Three Paths To Cannabis Profits: Village Farms, Green Thumb, And Jushi Show Divergent Strategies—Which Will Deliver?</a>

Analyst Color

Guidance

Eurozone

Retail Sales

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CRON

DBCCF

LOVFF

Are You Missing Out On This NASDAQ-Listed Weed Stock? Low-Cost Model Meets European Demand

In a report released yesterday, Michael Lewis from Truist Financial maintained a Hold rating on Easterly Government Properties (DEA – Research Repo...

Easterly Government Properties (DEA) Gets a Hold from Truist Financial

Earnings Metrics Of Several U.S. Office REITs Drop In Q3

Easterly Government And The DOGE: The Elon Musk Effect

3 Big Dividends Backed By High-Quality Assets

Easterly Government Properties Stock Price Got Far Too Cheap

KBWY: The 8.80% Dividend Yield May Start Growing Again In 2025

Jefferies lowered the firm's price target on Easterly Government Properties (DEA) to $12 from $15 and keeps a Buy rating on the shares as part of a...

Easterly Government Properties price target lowered to $12 from $15 at Jefferies

2 REITs That May Perform Poorly Under Trump

Truist lowered the firm's price target on Easterly Government Properties (DEA) to $12 from $13 and keeps a Hold rating on the shares as part of a 2...

Comments

Easterly Government Props

Easterly Government Props (DEA) オプション

Easterly Government Props (NYSE:DEA) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル